{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:05:16Z","timestamp":1777521916581,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T00:00:00Z","timestamp":1335225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To date, the safety and tolerability of proton pump inhibitors (<jats:styled-content style=\"fixed-case\">PPI<\/jats:styled-content>s) have been demonstrated in studies of up to 10\u00a0years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To report on the tolerability, safety and efficacy of up to 15\u00a0years' continuous treatment with pantoprazole in patients with severe acid\u2010peptic disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Following healing of endoscopically confirmed peptic ulcer or reflux oesophagitis during 4\u201312\u00a0weeks' treatment with pantoprazole (40\u201380\u00a0mg\/day), adult patients received open\u2010label maintenance treatment with pantoprazole (40\u2013160\u00a0mg\/day) for up to 15\u00a0years in a single centre combined study (10\u2010year initial study; 5\u2010year extension study). Safety assessments were carried out using endoscopy, clinical examination, clinical laboratory investigations, serum gastrin determination, gastric mucosal histology and mucosal endocrine cell quantification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The safety set comprised 142 patients. At 12\u00a0weeks, healing rates were 95.8%. During long\u2010term treatment, mean fasting gastrin levels rose from baseline to moderate levels throughout the study. Mean enterochromaffin\u2010like cell density showed a moderate initial increase during the first 3\u00a0years, remaining stable thereafter. These changes were not associated with any clinically relevant changes of the gastric mucosa. Patients with successful <jats:italic>Helicobacter pylori<\/jats:italic> eradication showed long\u2010term regression of antral and corpus gastritis during continued pantoprazole treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Daily pantoprazole maintenance therapy for up to 15\u00a0years for severe acid\u2010peptic disease is effective and well tolerated, with no identified safety concerns. The longest study to date, these data provide reassuring evidence for the long\u2010term safety of pantoprazole.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2012.05106.x","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T03:22:41Z","timestamp":1335324161000},"page":"37-47","source":"Crossref","is-referenced-by-count":47,"title":["Long\u2010term, open\u2010label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15\u00a0years in severe acid\u2010peptic disease"],"prefix":"10.1111","volume":"36","author":[{"given":"G.","family":"Brunner","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine University Medical School Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Athmann","sequence":"additional","affiliation":[{"name":"Center f\u00fcr Hepatogastroenterologie und HIV D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Nycomed GmbH Konstanz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2004.05.015"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00259.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/019262338801600220"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604183341603"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.2008.S35"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70135-1"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000048863"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4238"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01097.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199610000-00001"},{"key":"e_1_2_7_12_1","volume-title":"The Sydney System: A new classification of gastritis. World Congress on Gastroenterology Working Party Reports","author":"Misiewicz JJ","year":"1990"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651030-00012"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363010-00006"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0029(20000315)48:6<357::AID-JEMT6>3.0.CO;2-3"},{"key":"e_1_2_7_16_1","first-page":"303","article-title":"Clinical aspects of ECL\u2010cell abnormalities","volume":"71","author":"Hirschowitz BI","year":"1998","journal-title":"Yale J Biol Med"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000200921"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-3-199408010-00001"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9041231"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00768.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04310.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-008-0100-1"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(00)80016-3"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1999.0029900319"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.101634"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2012.05106.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2012.05106.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:56:19Z","timestamp":1700571379000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2012.05106.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,24]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1365-2036.2012.05106.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05106.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,24]]}}}